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Translation of noncoding common variant association signals
into meaningful molecular and biological mechanisms explaining
disease susceptibility remains challenging. For the type 2 di-
abetes association signal in JAZF1 intron 1, we hypothesized that
the underlying risk variants have cis-regulatory effects in islets or
other type 2 diabetes–relevant cell types. We used maps of ex-
perimentally predicted open chromatin regions to prioritize var-
iants for functional follow-up studies of transcriptional activity.
Twelve regions containing type 2 diabetes–associated variants
were tested for enhancer activity in 832/13 and MIN6 insulinoma
cells. Three regions exhibited enhancer activity and only
rs1635852 displayed allelic differences in enhancer activity; the
type 2 diabetes risk allele T showed lower transcriptional activity
than the nonrisk allele C. This risk allele showed increased bind-
ing to protein complexes, suggesting that it functions as part of
a transcriptional repressor complex. We applied DNA affinity
capture to identify factors in the complex and determined that
the risk allele preferentially binds the pancreatic master regulator
PDX1. These data suggest that the rs1635852 region in JAZF1
intron 1 is part of a cis-regulatory complex and that maps of open
chromatin are useful to guide identification of variants with alle-
lic differences in regulatory activity at type 2 diabetes loci.
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G
enome-wide association studies (GWAS) have
identified .50 genome-wide significant loci as-
sociated with type 2 diabetes to date (1). For
many of these loci, association signals are lo-
calized to nonprotein-coding intronic and intergenic
regions, which may contain variants that regulate gene
transcription. A primary challenge remains in the transi-
tion from GWAS locus discovery to identification of func-
tional variants underlying disease susceptibility. Tools are
needed to detect functional variants from the set of disease-
associated variants at a locus. FAIRE-seq (formaldehyde-
assisted isolation of regulatory elements) and DNase-seq
are two methods that identify nucleosome-depleted (open
chromatin) regions comprising active DNA regulatory
elements that include promoters, enhancers, silencers, and
insulators (2,3). Integration of associated variants identi-
fied through GWAS with tissue-relevant genome-wide
maps of open chromatin from the ENCODE Consortium
(4) and epigenomic maps from the Roadmap Epigenomics
Consortium (5) has great potential to facilitate identifica-
tion of regulatory variants (6–8).
JAZF1 (juxtaposed with another zinc finger protein) is
one such locus containing variants strongly associated with
type 2 diabetes (P = 5 3 10214) that are located within in-
tron 1 (9). JAZF1 encodes a putative transcription factor.
JAZF1 protein interacts with NR2C2 (nuclear receptor
subfamily 2, group C, member 2) protein and represses
NR2C2-mediated transactivation (10). NR2C2, also known
as TR4, is an orphan nuclear receptor targeting many genes
important in metabolism (11). Mice lacking Nr2c2 have
perinatal and postnatal hypoglycemia (12) and are pro-
tected from glucose intolerance and insulin resistance in-
duced with a high-fat diet (13). JAZF1 locus variants have
been associated with impaired b-cell function (14). The
function of JAZF1 as a transcriptional repressor of a gene
negatively influencing glucose metabolism suggests that
susceptibility alleles at this locus may result in decreased
JAZF1 transcription. Of note, islets from type 2 diabetes
donors display decreased JAZF1 expression, and higher
levels of islet JAZF1 are correlated with higher insulin se-
cretion and higher glycemic control (15). Single nucleotide
polymorphisms (SNPs) at the JAZF1 association signal in
intron 1 also are associated with height (16), and an in-
dependent signal (r2 = 0.024 with GWAS index SNP
rs849134) located.200 kb away is associated with prostate
cancer (17). Additionally, expression quantitative trait locus
(eQTL) analysis supports association of the type 2 diabetes
risk allele with altered JAZF1 transcript level in adipose
tissue, liver, and muscle (18–20).
To gain insight into the molecular mechanisms underlying
the type 2 diabetes association at JAZF1, we used maps of
open chromatin to guide identification of variants in potential
regulatory elements. Based on evidence of an effect in b-cell
function and insulin secretion (14,15), experiments were per-
formed in two available mammalian b-cell lines. We measured
transcriptional activity of prioritized variants using luciferase
reporter assays and report a candidate cis-acting SNP that
displays allele-specific enhancer activity. We also evaluated
allelic differences in protein binding and provide evidence of
a potential molecular mechanism for JAZF1 SNP effects.
RESEARCH DESIGN AND METHODS
Selection of SNPs for functional study. Variants were prioritized for
functional study based on linkage disequilibrium (LD) and evidence of islet
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open chromatin. All five SNPs in high LD (r2 $ 0.8; CEPH [Utah residents with
ancestry from northern and western Europe] [CEU] 1,000G, March 2012 re-
lease) with the GWAS index SNP rs849134 and present in an islet FAIRE peak
(8) or DNase peak (6) were tested for evidence of differential transcriptional
activity. We also tested three SNPs based on only high LD and four other SNPs
in the region (low LD SNPs; r2 , 0.5; Supplementary Table 1).
Cell culture. Two insulinoma cell lines, rat-derived 832/13 (21) (C.B. Newgard,
Duke University, Durham, NC) and mouse-derived MIN6 (22) were maintained
at 37°C with 5% CO2. The 832/13 cells were cultured in RPMI 1640 (Invitrogen,
Carlsbad, CA) supplemented with 10% FBS, 1 mmol/L sodium pyruvate, 2
mmol/L L-glutamine, 10 mmol/L HEPES, and 0.05 mmol/L b-mercaptoethanol.
MIN6 cells were cultured in DMEM (Invitrogen) supplemented with 10% FBS,
1 mmol/L sodium pyruvate, and 0.1 mmol/L b-mercaptoethanol. HepG2 he-
patocellular carcinoma cells were cultured in MEM-a (Invitrogen) supple-
mented with 10% FBS, 1 mmol/L sodium pyruvate, and 2 mmol/L L-glutamine.
Differentiated 3T3-L1 adipocyte cells were maintained in DMEM supple-
mented with 10% FBS, 1 mmol/L dexamethasone, 0.5 mmol/L IBMX, and 1 ug/mL
insulin.
Generation of luciferase reporter constructs, transient DNA transfection,
and luciferase reporter assays. The 150- to 200-bp fragments surrounding
each of 12 SNPs were PCR-amplified (Supplementary Table 2) from DNA of
individuals homozygous for risk and nonrisk alleles. Restriction sites for
KpnI and XhoI were added to primers during amplification, and the resulting
PCR products were digested with KpnI and XhoI and cloned in both ori-
entations into the multiple cloning site of the minimal promoter-containing
firefly luciferase reporter vector pGL4.23 (Promega, Madison, WI). Frag-
ments are designated as forward or reverse based on their orientation in
the genome with respect to the JAZF1 coding sequence. Two to four in-
dependent clones for each allele for each orientation were isolated, verified
by sequencing, and transfected in duplicate into 832/13 and MIN6 b-cell lines.
Approximately 13 1025 cells per well were seeded in 24-well plates. At 80%
confluency, cells were cotransfected with luciferase constructs and Renilla
control reporter vector (phRL-TK; Promega) at a ratio of 30:1 for MIN6 using
Lipofectamine 2000 (Invitrogen) and at a ratio of 10:1 for 832/13 cells using
FUGENE-6 (Roche Diagnostics, Indianapolis, IN). At 48 h after transfection,
cells were lysed with passive lysis buffer (Promega), and luciferase activity
was measured using the Dual-Luciferase Assay System (Promega). To control
for transfection efficiency, raw values for firefly luciferase activity were di-
vided by raw Renilla luciferase activity values, and fold change was calculated
as normalized luciferase values divided by pGL4.23 minimal promoter empty
vector control values. Data are reported as the fold change in mean (6SE)
relative luciferase activity per allele. A two-sided t test was used to compare
luciferase activity between alleles. Experiments in MIN6 and 832/13 cells were
performed on a second independent day and yielded comparable allele-
specific results.
Electrophoretic mobility shift assay. Nuclear cell extracts were prepared
from 832/13, MIN6, HepG2, and 3T3-L1 cells using the NE-PER nuclear and
cytoplasmic extraction kit (Thermo Scientific) according to the manufacturer’s
instructions. Protein concentration was measured with a BCA protein assay
(Thermo Scientific), and lysates were stored at 280°C until use. The 17-bp
oligonucleotides were designed to the sequence surrounding rs1635852 risk or
nonrisk alleles as follows: sense 59 biotin-CTGATTAA[T/C]TCACTTAG 39 and
antisense 59 biotin-CTAAGTGA[G/C]TTAATCAG39 (SNP allele in bold). Double-
stranded oligonucleotides for the risk and nonrisk alleles were generated
by incubating 50 pmol complementary oligonucleotides at 95°C for 5 min,
followed by gradual cooling to room temperature. Electrophoretic mobility
shift assays (EMSAs) were performed using the LightShift Chemiluminescent
EMSA Kit (Thermo Scientific). Binding reactions were set-up as 13 binding
buffer, 50 ng/mL poly (dI$dC), 3 mg nuclear extract, and 20 fmol labeled probe
in a final volume of 20 mL. For competition reactions, 67-fold excess of un-
labeled double-stranded oligonucleotides for either the risk or the nonrisk
allele were included. Reactions were incubated at room temperature for 25
min. For supershift assays, 4 mg polyclonal antibodies against PDX1 (SC-
146623; Santa Cruz Biotechnology) or CUX1 (SC63273; Santa Cruz Bio-
technology) were added to the binding reaction and incubation proceeded
for a further 25 min. Binding reactions were subjected to nondenaturing
PAGE on DNA retardation gels in 0.53 TBE (Invitrogen), transferred to nylon
membranes (Invitrogen), and cross-linked on an ultraviolet light cross-linker
(Stratagene). Biotin labeled DNA–protein complexes were detected by
chemiluminescence. EMSAs were performed on a second independent day
and yielded comparable results.
DNA affinity capture assay. Nuclear extracts (prepared as for EMSA) were
dialyzed against dialysis buffer (20 mmol/L Tris/HCl [pH 7.9], 70 mmol/L KCl,
1 mmol/L EDTA) in a Slide-A-Lyzer MINI Dialysis Device (Thermo Scientific).
Dialyzed nuclear extracts (300 mg) were precleared with 100 mL streptavidin-
agarose dynabeads (Invitrogen) coupled to biotin-labeled scrambled control
oligonucleotides. This preclearing step was performed to reduce nonspecific
binding of nuclear protein. For DNA-protein binding reactions, 40 pmol of
biotin-labeled probe either for rs1635852 allele (same probe as for EMSA) or
for a scrambled control were incubated with 300 mg nuclear extract, binding
buffer (10 mmol/L Tris, 50 mmol/L KCL, 1 mmol/L DTT), 0.5 mg/mL poly
(dI$dC), and H2O to total 450 mL at room temperature for 30 min with rotation;
100 mL (1 mg) of streptavidin-agarose dynabeads were added and the reaction
was incubated for a further 20 min. Beads were washed four times in binding
buffer with 0.05% NP-40 and once in binding buffer without NP-40. DNA-bound
proteins were eluted in 13 reducing sample buffer (Invitrogen) by heating for
10 min at 70°C. Proteins were separated on NuPAGE denaturing gels and
protein bands were stained with SYPRO-Ruby. Protein bands displaying dif-
ferential binding between rs1635852 alleles (but not scrambled control) were
excised from the gel and subjected to matrix-assisted laser desorption time-of-
flight/time-of-flight tandem mass spectrometry (MS) and analysis at the Uni-
versity of North Carolina proteomics core facility. For peptide identification,
all MS/MS spectra were searched against all entries in the National Center for
Biotechnology Information nonredundant database using GPS Explorer soft-
ware version 3.6 (ABI) and Mascot (MatrixScience) search algorithm. Mass
tolerance was 80 ppm for precursor ions and 0.6 Da for fragment ions were
used. In addition, two missed cleavages were allowed and oxidation of me-
thionine was a variable modification.
RESULTS
Characterization of type 2 diabetes–associated SNPs
in JAZF1 intron 1 with regulatory potential. To dis-
tinguish potentially functional regulatory variants from
proxy variants in high LD at the type 2 diabetes–associated
JAZF1 locus, we selected variants in high LD (r2 . 0.8)
with GWAS index SNP rs849134. To further prioritize
variants for functional analysis, we used genome-wide
maps of open chromatin (Fig. 1A, C) in available type 2
diabetes–relevant cell types, including pancreatic islets,
liver hepatocytes, and skeletal muscle myotubes. DNase-
seq and FAIRE-seq are well-established methods identify-
ing both overlapping and unique nucleosome-depleted
regions that include active regulatory elements (23). We
also evaluated variant position with respect to the histone
modifications H3K4me1 and H3K9ac, which are post-
translational marks associated with enhancer regions (Fig.
1D) (24,25). Of 15 variants meeting the LD threshold, five
SNPs were found to overlap an islet FAIRE peak or DNase
peak and displayed some evidence of H3K4me1 or H3K9ac
signal (Fig. 1). Whereas enhancer histone modification
profiles served to support evidence of function, they did
not help for SNP prioritization because of an overall high
background signal (Fig. 1D). No SNPs overlapped with
DNase or FAIRE peaks in the other cell types examined
(data not shown).
rs1635852 displays allele-specific enhancer activity in
islet cells. To evaluate transcriptional activity of the five
SNPs predicted to be in islet-regulatory regions, we cloned
;200 bp surrounding each SNP allele into a minimal pro-
moter reporter vector and measured luciferase activity in
two b-cell lines, 832/13 rat insulinoma and MIN6 mouse
insulinoma cells. Two to four independent clones for each
allele were generated and enhancer activity was measured
in duplicate for each clone. Of the five SNPs in open
chromatin region, three displayed evidence of enhancer
activity compared with an empty vector control in both
cell lines in the forward orientations –rs1635852, rs849133,
and rs849142 (Fig. 2A, B). Of these, rs1635852 showed
differential allelic enhancer activity in both orientations in
both cell lines. The risk allele T showed significantly de-
creased luciferase activity compared with the nonrisk al-
lele C (forward: 832/13 [P = 7.83 1025] and MIN6 [P = 1.03
1025]; reverse: 832/13 [P = 1.8 3 1022] and MIN6 [P = 8.3 3
1024]; Fig. 2A, B). Enhancer activity at rs1635852 represents
.2-fold and 1.7-fold increases in transcriptional activity
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relative to the risk allele in forward and reverse orienta-
tion, respectively, in both cell lines. No allele-specific en-
hancer activity was observed for rs849133 and rs849142.
Transcriptional activity was evaluated in seven other type
2 diabetes–associated SNPs in JAZF1 intron 1 not over-
lapping islet FAIRE or DNase peaks, three SNPs in high LD
and four SNPs in lower LD, with GWAS index SNP
rs849134 (Supplementary Table 1). None of these seven
SNPs showed evidence of enhancer activity in 832/13 or
MIN6 cells compared with an empty vector control (Sup-
plementary Fig. 1). Taken together, these data demon-
strate that rs1635852 exhibits allelic differences in
transcriptional enhancer activity and suggest it functions
within a candidate cis-regulatory element at the JAZF1
intronic type 2 diabetes–associated locus.
Differential protein binding to rs1635852 alleles. We
next asked whether alleles of rs1635852 differentially af-
fect DNA binding to nuclear proteins. Biotin-labeled
probes surrounding the T (risk) or C (nonrisk) allele of
rs1635852 were incubated with 832/13 or MIN6 nuclear
lysate and subjected to EMSA. Band shifts indicative of
multiple DNA–protein complexes were observed for both
alleles of rs1635852 (Fig. 3A, C, D). In the EMSA from 832/
13 nuclear extract, three protein complexes were observed
for the probe containing the T allele that were either less
intense (arrow a) or not present (arrow b, c) for the probe
containing the C allele. In the EMSA from MIN6 nuclear
extract, two protein complexes were observed for the
probe containing the T allele that were either less intense
(arrow a) or not present (arrow b) for the probe containing
the C allele. Taken together, these data suggest differential
protein binding dependent on the rs1635852 allele. Com-
petition of labeled T allele with excess unlabeled T allele
more efficiently competed away allele-specific bands than
excess unlabeled C allele, demonstrating allele-specificity
of the protein–DNA complexes (Fig. 3A). Based on these
results, we hypothesized that rs1635852 is located in
a binding site for a transcriptional regulator complex that
may be disrupted by the rs1635852 C allele.
Identification of proteins binding rs1635852. We
sought to identify factors in the protein complex binding
rs1635852 using a DNA-affinity capture assay. The same
biotin-labeled probes used for EMSA including the
rs1635852 T or C alleles were incubated with 832/13 nu-
clear lysates, and the resulting DNA–protein complexes
were isolated and subjected to SDS-PAGE. We observed
two protein bands showing differential intensity consistent
with increased binding to the T allele (Fig. 3B). These
bands were identified as transcription factors PDX1 (pan-
creatic duodenal homeobox 1) and CUX1 (cut-like ho-
meobox 1) using MALDI TOF/TOF MS.
To validate binding of rs1635852 to these transcription
factors, we performed supershift experiments incubating
DNA–protein complexes with antibodies for either PDX1
or CUX1. Incubation of the T allele–protein complex with
PDX1 antibody completely disrupted protein–DNA binding
at complex c (832/13; Fig. 3C, arrow c) and reduced
binding to protein complex b (Fig. 3C, 832/13; Fig. 3D,
MIN6, arrow b). A PDX1-mediated supershift was ob-
served in MIN6 cells for both rs1635852 alleles (Fig. 3D).
A consistent supershift band was not observed in 832/13
cells and may have been masked by presence of a larger
DNA–protein complex (Fig. 3C, arrow d). No evidence of
a PDX-mediated complex disruption or band supershift
was observed in 3T3-L1 and HepG2 nuclear extracts
(Supplementary Fig. 2A, B). In contrast, incubation with
CUX1 only slightly reduced binding to complex b and c
(Fig. 3C, D). These data provide evidence that the
rs1635852 T allele binds PDX1 in an allele-specific manner.
Consistent with this result, a search of the JASPAR CORE
database (26) shows that only the sequence containing the
rs1635852 T allele is predicted as a PDX1 consensus core-
binding motif.
DISCUSSION
At many of the loci identified through GWAS, association
signals are localized to intronic and intergenic regions and
FIG. 1. Regulatory potential at type 2 diabetes–associated SNPs at the JAZF1 locus. A: Twelve high LD SNPs (r2 ‡ 0.80 with GWAS index SNP
rs849134). Closed arrows indicate five SNPs overlapping open chromatin marks tested for allele-specific transcriptional activity. Open arrows
indicate three SNPs without evidence of open chromatin and tested for allele-specific transcriptional activity for comparison. Four high LD SNPs
without evidence of open chromatin were not tested for allele-specific transcriptional activity. B: FAIRE peaks identified in three islet samples.
C: DNase hypersensitivity peaks identified in two pooled islet samples from the ENCODE Consortium. D: Islet H3K4me1 and H3K9ac histone
modifications from the Roadmap Epigenomics Consortium. Three high LD indels that do not overlap with open chromatin and lack reference SNP
ID numbers (rs#) are shown. Four additional low LD SNPs located 12–20 kb proximal to the region shown were tested for allele-specific tran-
scriptional activity. Image is taken from University of California, Santa Cruz, genome browser, February 2009 (GRCh37/hg19) assembly (http://
genome.ucsc.edu) (38).
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are hypothesized to harbor nonpromoter regulatory ele-
ments altering gene transcription. In the current study, we
focused on the type 2 diabetes–associated signal in JAZF1
intron 1 and asked whether variants at this locus displayed
allele-specific transcriptional enhancer activity consistent
with a cis-regulatory effect. We used maps of open chro-
matin to guide identification of variants with allelic differ-
ences in transcriptional activity. We provide evidence that
rs1635852 is a strong candidate for a differential effect on
transcriptional enhancer activity, likely through altered
binding in a regulatory complex containing PDX1. SNPs
evaluated include the JAZF1 lead SNPs from two recent
descriptions of high-density genotyping at this locus (27,28).
A challenge in mechanistic studies of GWAS signals is
differentiating among the numerous SNPs to identify those
underlying the disease association. On the basis of the
assumption that a common variant with modest effect
likely underlies the association at JAZF1, we aligned high
LD variants (r2 $ 0.8; n = 14) in JAZF1 intron 1 with active
DNA regulatory elements identified by DNase-seq and
FAIRE-seq and found that five variants overlapped with
islet-regulatory regions. It is important to recognize that
current available data sets for FAIRE and DNase may not
be complete and that SNPs in lower LD (r2 , 0.8) with the
index SNP also may affect gene expression or activity.
Therefore, additional functional SNPs may exist at the
JAZF1 type 2 diabetes locus that were not examined in
this study.
Notably, all five SNPs found in islet open chromatin
regions overlapped with FAIRE peaks only, perhaps
reflecting a recent observation of twice as many FAIRE
sites as DNase sites when looking across multiple cell
types (23). Cell-selective open chromatin tends to be lo-
cated away from the transcription start site (23), suggest-
ing that regulatory elements in intron 1 of JAZF1 may be
unique to islets. There was no evidence of overlap with
open chromatin for associated SNPs in other available
relevant tissue datasets examined. However, we cannot
rule out that there may be shared regulatory regions in
tissues for which FAIRE or DNase data are not currently
available.
Choosing the correct tissue type for testing activity of
functional variants is critical because many regulatory
elements act in a tissue-specific manner (25,29). Based on
our observation of type 2 diabetes–associated SNPs in
regions of islet open chromatin, we measured transcrip-
tional activity in two available mammalian islet cell mod-
els, 832/13 and MIN6 cells from rat and mouse,
respectively. Importantly, we found similar fold changes in
allelic transcriptional activity across the two cell types,
suggesting that measurement of enhancer activity may be
consistent across species.
Of three SNPs predicted to be located in active regula-
tory regions that displayed enhancer activity, only
rs1635852 demonstrated allele-specific effects, making it
a lead functional candidate among the SNPs tested. The T
allele (risk) of rs1635852 displayed reduced enhancer ac-
tivity relative to the C allele (nonrisk), suggesting that re-
duced expression of islet JAZF1 may be associated with
type 2 diabetes. We hypothesized that alleles of rs1635852
might differentially bind a transcription factor, resulting in
altered gene transcription, and our analysis of protein
binding revealed complexes that favored the rs1635852 T
allele in 832/13 and MIN6 insulinoma cells. rs1635852 also
showed a differential protein binding pattern in EMSA
using 3T3-L1 mouse adipocyte and HepG2 human hepa-
tocyte nuclear extracts but the pattern of binding differed
from that of islet extracts with alternate DNA–protein
complexes present (Supplementary Fig. 2A, B). Using DNA
affinity capture, we identified PDX1 and CUX1 as two
proteins that showed increased binding to the T allele and
validated that in 832/13 and MIN6 cells, PDX1 antibody
disrupted at least one of the protein complexes formed
preferentially in the presence of the T allele. Our results
suggest that the DNA sequence surrounding rs1635852
may bind protein differentially in multiple cell types but
that the protein complexes involved likely differ because
PDX1 binding was exclusive to insulinoma cell types. The
fourth base of the PDX1 consensus core DNA binding
motif (TAAT) is altered by the rs1635852 C allele. In con-
trast, the CUX1 consensus sequence, ATA (30), is not
found in the 17 bp DNA sequence that includes rs1635852,
suggesting that CUX1 may not directly bind DNA in this
region, but instead may be bound to a DNA-binding protein
in the complex. Additional transcription factors not iden-
tified here also may play a role in enhancer activity at
rs1635852.
PDX1 plays a central role in embryonic development of
pancreatic islets and in maintenance of normal glucose
FIG. 2. rs1635852 alleles display differential transcriptional activity.
A: Enhancer activity was tested in 832/13 cells for the type 2 diabetes
risk (white bars) and nonrisk (black bars) alleles of five SNPs in can-
didate regulatory regions in forward (Fwd) and reverse (Rev) ori-
entations with respect to JAZF1. Significant allele-specific enhancer
activity was observed for rs1635852. The rs1635852 risk allele T shows
less transcriptional activity than the nonrisk allele C in both ori-
entations with respect to a minimal promoter vector. B: rs1635852 risk
allele displays similar decreased transcriptional activity in MIN6 cells.
Error bars represent SE of 2–4 independent clones for each allele.
Results are expressed as fold change compared with empty vector
control. P values were calculated by a two-sided t test.
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homeostasis in adult islets. Heterozygous mutations in
PDX1 result in early and late onset of diabetes in humans
(31–33). PDX1 binds to DNA sequences containing the
consensus TAAT motif and subsequently recruits protein
complexes that regulate transcription of several b-cell
genes that include INS and GLUT2 (34,35). Whereas the
role of PDX1 as a gene activator is well-established, a recent
analysis of genome-wide PDX1 occupancy using chromatin
immunoprecipitation highlights a strong role for PDX1 as
a transcriptional repressor (36). The same study demon-
strates that PDX1 binds across 4,470 human genes, in-
cluding to five regions of JAZF1, with 48% of binding sites
being located in introns (36). Our data demonstrate reduced
transcriptional activity with the rs1635852 T allele, sug-
gesting that in this instance PDX1 may be functioning as
part of a transcriptional repressor complex. Further
experiments are necessary to validate binding to rs1635852
in human islets with known genotypes and to elucidate
other key factors in the repressor complex.
Although JAZF1 is not confirmed as the affected gene at
this locus, eQTL analysis supports association of the type 2
diabetes risk allele with decreased JAZF1 transcript levels in
adipose tissue that is consistent with the direction of
transcriptional activity we observed in islet cells (18).
rs1635852 or proxy SNPs (r2 . 0.95) are reported associated
with JAZF1 transcript levels in at least three tissues—liver,
adipose, and muscle (18–20). In addition, JAZF1 expression
is decreased in islets from type 2 diabetes donors (15). The
strongest evidence of a biological basis for JAZF1 in type 2
diabetes susceptibility comes from observations that JAZF1
protein binds and represses action of the metabolic regulator
NR2C2 (10). Nr2c2-deficient mice show reduced hepatic
triglyceride levels, reduced lipid accumulation in adipose
tissue, and are resistant to glucose intolerance and insulin
resistance (13). NR2C2 is expressed in pancreatic islets (37),
but to our knowledge it has not been well-characterized. Our
data suggesting differential allelic transcription in JAZF1
may allude to a role for NR2C2 in b-cell gene regulation.
Recent chromatin immunoprecipitation analysis of NR2C2
binding sites across the genome revealed that NR2C2 con-
trols genes involved in fundamental biologic processes
across diverse cell types and in targeting genes in a cell-
specific manner (11). It is also possible that JAZF1 may serve
as a cofactor of additional nuclear receptors, although it does
not regulate transcriptional activation by two tested recep-
tors, PPARA and RORG (10).
FIG. 3. Alleles of rs1635852 differentially bind PDX1 in rat 832/13 and mouse MIN6 insulinoma cells. A: EMSA using 832/13 nuclear extract shows
differential protein–DNA binding of rs1635852 alleles. The probe containing risk allele T shows increased protein binding (arrows a, b, c) com-
pared with the probe containing nonrisk allele C. Excess unlabeled specific probe containing the T allele (T-comp) more efficiently competed away
allele-specific bands than unlabeled probe for the C allele (C-comp). To enhance visualization of protein complexes, free biotin-labeled probe is
not shown. B: DNA affinity-capture identified differential binding of CUX1 and PDX1 at rs1635852 alleles in 832/13 cells. C: Incubation of 832/13
nuclear extract with PDX1 antibody disrupts the DNA–protein complex formed with T allele–containing DNA probe (arrows b and c). The presence
of a nonallele-specific complex (arrow d) may mask a PDX1-mediated supershift. D: Incubation of MIN6 nuclear extract with PDX1 antibody
disrupts the DNA–protein complex formed with T allele–containing DNA probe (arrow b) and results in a band supershift. (A high-quality color
representation of this figure is available in the online issue.)
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In summary, we demonstrate that maps of open chro-
matin are a useful resource to guide identification of var-
iants in cis-acting regulatory elements at type 2 diabetes
susceptibility loci, and we provide evidence that rs1635852,
a SNP at the JAZF1 type 2 diabetes–associated locus, dif-
ferentially affects transcriptional activity through binding of
a regulatory protein complex that includes PDX1.
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